A U.S. Senate committee grilled Novo Nordisk CEO Lars Jorgensen about the exorbitant prices of the company's weight-loss drugs Ozempic and Wegovy. Lawmakers demanded answers and explored potential solutions to make these life-changing medications more affordable.
A U.S. Senate committee held a hearing on Tuesday to discuss popular drug maker Novo Nordisk lowering prices for blockbuster weight-loss drugs Ozempic and Wegovy . Lawmakers pressed CEO Lars Jorgensen, who shifted a lot of the blame to the pharmacy benefits managers. Jorgensen said that for every dollar the company makes, 74 cents goes to PBMs. C. Michael White is a professor in the School of Pharmacy at the University of Connecticut.
He said some 'They're going to cost you a little over $1,000 a month,' said White. Drug maker Novo Nordisk makes two of those drugs, Ozempic and Wegovy. The company's CEO discussed the drugs' high prices on Tuesday.Senator Bernie Sanders, I-Vt., who chairs the committee, demanded answers as to why the drugs cost so much.Sanders said Americans pay $969/month for Ozempic compared to $155 in Canada and $59 in Germany. Jorgensen argues the prices aren't just determined by his company. 'It is clear patients too often struggle to navigate the complex U.S. healthcare system,' said Jorgensen. Madeline Summerville, an attorney at Georgia Trail Consulting said that Tuesday's hearing was an opportunity for lawmakers to directly ask why Americans are paying so much. 'They wanted the person who was the CEO of the company to come and account for why they're charging so much,' Summerville said. Jorgensen did agree to meet with pharmacy benefits managers to discuss the possibility of lowering prices but Summerville believes to get to the root of the problem more needs to be done
Ozempic Wegovy Novo Nordisk Senate Hearing Drug Prices
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ozempic maker Novo Nordisk testifies before Senate committee on weight loss drug pricesNovo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on Tuesday.
Read more »
Novo Nordisk CEO Defends Ozempic Price In Senate TestimonyTy Roush is a New York City-based breaking news reporter who frequently covers Russia’s invasion of Ukraine, the automotive industry and sports money. He joined Forbes in 2022 and has covered Exxon acquiring Pioneer for nearly $60 billion, a mysterious respiratory illness affecting dogs across the U.S.
Read more »
Sanders Calls BS on Novo Nordisk Excuses for Sky-High Prices of Ozempic, WegovyJake Johnson is a senior editor and staff writer for Common Dreams.
Read more »
Bernie Sanders grills Novo Nordisk CEO on price of Ozempic, other weight-loss drugsSen. Bernie Sanders grilled Novo Nordisk's CEO Lars Jorgensen over the cost of the company's weight loss and diabetes medications, Ozempic and Wegovy.
Read more »
Ozempic, Wegovy maker Novo Nordisk faces hearing over high cost of weight loss drugsBlockbuster drugs Ozempic and Wegovy have sparked conversation and changed weight loss worldwide. In an exclusive interview, NBC News’ Megan Fitzgerald sits down with Novo Nordisk CEO Lars Fruergaard Jørgensen who helmed it all, and presses him on the high price, drug shortages, and long-term effects.
Read more »
Novo Nordisk CEO Defends High Ozempic, Wegovy Prices at Congressional HearingNovo Nordisk CEO Lars Jorgensen faced intense scrutiny from lawmakers on Tuesday over the high prices of the company's weight-loss drugs Ozempic and Wegovy. Jorgensen argued that pharmacy benefit managers (PBMs) are responsible for a significant portion of drug costs, but lawmakers pressed him to take action to lower prices for American patients.
Read more »